Haploidentical stem cell transplantation for the treatment of leukemia: current status

References

• Chang YJ, Huang XJ. Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol 2012;19(6):454-61
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119(5):978-85
   PubMed Web of Science ®Google Scholar
• Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013;31(10):1310-16
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013;121(5):849-57
   PubMed Web of Science ®Google Scholar
• Chen J, Wang RX, Chen F, et al. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant 2014;49(2):206-11
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2014;20(3):314-18
   PubMed Web of Science ®Google Scholar
• Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Am Soc Hematol Educ Program 2012;2012:230-6
   PubMedGoogle Scholar
• Raj K, Pagliuca A, Bradstock K, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014;20(6):890-5
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant 2014;49(7):873-9
   PubMed Web of Science ®Google Scholar
• Liu DH, Xu LP, Liu KY, et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transplant 2013;48(12):1519-24
   PubMed Web of Science ®Google Scholar
• Chen XH, Zhang C, Zhang X, et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009;15(2):266-73
   PubMed Web of Science ®Google Scholar
• Fuchs EJ. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol 2012;19(6):440-7
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Kim DY, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011;118(9):2609-17
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23(15):3447-54
   PubMed Web of Science ®Google Scholar
• Handgretinger R. Negative depletion of CD3+ and TcRalphabeta+ T cells. Curr Opin Hematol 2012;19(6):434-9
   PubMed Web of Science ®Google Scholar
• Lang P, Teltschik HM, Feuchtinger T, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol 2014;165(5):688-98
   PubMed Web of Science ®Google Scholar
• Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011;118(23):6006-17
   PubMed Web of Science ®Google Scholar
• Martelli MF, Di Ianni M, Ruggeri L, et al. “Designed” grafts for HLA-haploidentical stem cell transplantation. Blood 2014;123(7):967-73
   PubMed Web of Science ®Google Scholar
• Tischer J, Stemmler HJ, Engel N, et al. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol 2013;92(10):1379-88
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Haploidentical bone marrow transplantation without T-cell depletion. Semin Oncol 2012;39(6):653-63
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20(4):440-9
   PubMed Web of Science ®Google Scholar
• Mo XD, Xu LP, Liu DH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013;88(6):497-502
   PubMed Web of Science ®Google Scholar
• Stern M, Ruggeri L, Mancusi A, et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008;112(7):2990-5
   PubMed Web of Science ®Google Scholar
• Wang HT, Chang YJ, Xu LP, et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone marrow Transplant 2014;49(7):927-33
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu DH, Liu KY, et al. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(2):283-90
   PubMed Web of Science ®Google Scholar
• Zhao XY, Chang YJ, Huang XJ. Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences? Biol Blood Marrow Transplant 2011;17(10):1436-42
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107(8):3065-73
   PubMed Web of Science ®Google Scholar
• Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009;15(14):4777-83
   PubMed Web of Science ®Google Scholar
• Yang K, Si Y, Chen H, et al. Comparative study of the efficacy of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-haploidentical related and unrelated donors in the treatment of leukemia. Acta Haematol 2014;131(1):37-44
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vicent M, Molina B, Andion M, et al. Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. Eur J Haematol 2011;87(1):46-53
   PubMed Web of Science ®Google Scholar
• Rocha V, Aversa F, Labopin M, et al. Outcomes of unrelated cord blood and haploidentical transplantation in adults with acute leukaemia. Blood 2005;106:abstract 301
   Google Scholar
• Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol 2013;91(4):304-14
   PubMed Web of Science ®Google Scholar
• Casucci M, Perna SK, Falcone L, et al. Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene. Mol Ther 2013;21(2):466-75
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6):641-50
   PubMed Web of Science ®Google Scholar
• Ogawa H, Ikegame K, Kaida K, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol 2008;36(1):1-8
   PubMed Web of Science ®Google Scholar
• Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012;97(10):1523-31
   PubMed Web of Science ®Google Scholar
• Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011;118(24):6438-45
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012;39(6):683-93
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339(17):1186-93
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Blood 2010;115(17):3437-46
   PubMed Web of Science ®Google Scholar
• Handgretinger R. New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 2012;39(6):664-73
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117(14):3921-8
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B-cells in children with non-malignant disorders. Blood 2014;124(5):822-6
   PubMed Web of Science ®Google Scholar
• Huang XJ, Zhu HH, Chang YJ, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 2012;119(23):5584-90
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood marrow Transplant 2009;15(2):257-65
   PubMed Web of Science ®Google Scholar
• Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T cell exhaustion during effective human anti-leukemia responses to donor lymphocyte infusion. Blood 2014;123(9):1412-21
   PubMed Web of Science ®Google Scholar
• Xiao-Jun H, Lan-Ping X, Kai-Yan L, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008;40(6):444-55
   PubMed Web of Science ®Google Scholar
• Patriarca F, Luznik L, Medeot M, et al. Experts’ considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013;19(1):117-22
   PubMed Web of Science ®Google Scholar
• Tischer J, Engel N, Fritsch S, et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant 2014;49(7):895-901
   PubMed Web of Science ®Google Scholar
• Liu DH, Xu LP, Liu KY, et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transplant 2013;48(12):1519-24
   PubMed Web of Science ®Google Scholar
• Chang YJ, Zhao XY, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20(4):440-9
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant 2013;19(2):180-4
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18(12):1835-44
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA- haplotype-mismatched transplant? Blood 2014;124(6):843-50
   PubMed Web of Science ®Google Scholar
• Leung W, Campana D, Yang J, et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118(2):223-30
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t (8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013;121(20):4056-62
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119(14):3256-62
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Sierra J, Wang T, et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant 2011;17(5):640-8
   PubMed Web of Science ®Google Scholar
• Mo XD, Zhao XY, Liu DH, et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplant 2014;49(8):1070-5
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Kan F, Woo Ahn K, et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 2010;116(19):4007-15
   PubMed Web of Science ®Google Scholar
• Ballen KK, Koreth J, Chen YB, et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012;119(9):1972-80
   PubMed Web of Science ®Google Scholar
• Yan CH, Jiang Q, Wang J, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant 2014;20(9):1314-21
   PubMed Web of Science ®Google Scholar
• Sebrango A, Vicuna I, de Laiglesia A, et al. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes. Best practice & research. Clin Haematol 2010;23(2):259-74
   Google Scholar
• Fernandez MN, Regidor C, Cabrera R, et al. Cord blood transplants: early recovery of neutrophils from co-transplanted sibling haploidentical progenitor cells and lack of engraftment of cultured cord blood cells, as ascertained by analysis of DNA polymorphisms. Bone Marrow Transplant 2001;28(4):355-63
   PubMed Web of Science ®Google Scholar
• Guo M, Hu KX, Liu GX, et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol 2012;30(33):4084-90
   PubMed Web of Science ®Google Scholar
• Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011;117(3):936-41
   PubMed Web of Science ®Google Scholar
• Cignetti A, Ruella M, Elia A, et al. Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: description of its use in high risk patients. Am J Hematol 2013;88(8):720-1
   PubMed Web of Science ®Google Scholar
• Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev 2013;27(1):55-62
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097-100
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28(6):955-9
   PubMed Web of Science ®Google Scholar
• Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014;20(5):696-704
   PubMed Web of Science ®Google Scholar
• Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008;112(9):3574-81
   PubMed Web of Science ®Google Scholar
• Jiang Q, Xu LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011;117(11):3032-40
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Miyamoto T, Eto T, et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study). J Hematol Oncol 2013;6:14
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120(9):1868-76
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Curr Opin Hematol 2013;20(2):86-92
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31(31):3889-97
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 Trial. J Clin Oncol 2014;32(15):1595-604
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011;118(2):282-8
   PubMed Web of Science ®Google Scholar
• Double cord versus haploidentical (blood and marrow transplant clinical trials network #1101). Available from: http://clinicaltrials.gov/show/NCT01597778
   Google Scholar